Related Experiment Video
Updated: Oct 14, 2025

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
Novel in vitro Experimental Approaches to Study Myelination and Remyelination in the Central Nervous System
Davide Marangon1, Nicolò Caporale2,3, Marta Boccazzi4
1Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy.
Insights
New experimental models, including iPSC-derived cells and 3D brain cultures, advance the study of myelin and remyelination for diseases like multiple sclerosis.
Area of Science:
- Neuroscience
- Cell Biology
- Biotechnology
Background:
- Myelin, a lipid sheath, is crucial for fast nerve conduction, formed by oligodendrocyte (OL) membranes.
- Oligodendrocyte precursor cells (OPCs) differentiate and mature to form myelin.
- Studying myelination and remyelination is vital for understanding neurological disorders.
Purpose of the Study:
- To review novel experimental approaches for studying myelination and remyelination.
- To explore the implications of these methods for identifying remyelinating agents.
- To discuss applications for human diseases, particularly multiple sclerosis.
Main Methods:
- Co-culturing OPCs with neurons for in vitro myelination studies.
- Utilizing in vivo models to study demyelination and remyelination.
- Employing induced pluripotent stem cells (iPSCs) for human cell-based models.
- Developing 3D-printed culture chambers and biomaterial scaffolds for controlled cell interactions.
- Investigating iPSC-derived 3D brain cultures (organoids) for developmental studies.
Main Results:
- In vitro and in vivo models provide insights into myelination and remyelination.
- Human iPSCs offer personalized disease modeling and drug screening potential.
- 3D bioengineered systems allow controlled study of cell-cell interactions and mechanosensory properties.
- Organoids show promise for studying early brain development, with emerging applications for myelination.
Conclusions:
- Recent technological advancements significantly enhance the study of myelination and remyelination.
- These novel methods, including iPSC technology and organoids, are critical for discovering remyelinating therapies.
- The reviewed approaches hold promise for treating human diseases like multiple sclerosis.
Abstract:
Myelin is the lipidic insulating structure enwrapping axons and allowing fast saltatory nerve conduction. In the central nervous system, myelin sheath is the result of the complex packaging of multilamellar extensions of oligodendrocyte (OL) membranes. Before reaching myelinating capabilities, OLs undergo a very precise program of differentiation and maturation that starts from OL precursor cells (OPCs). In the last 20 years, the biology of OPCs and their behavior under pathological conditions have been studied through several experimental models. When co-cultured with neurons, OPCs undergo terminal maturation and produce myelin tracts around axons, allowing to investigate myelination in response to exogenous stimuli in a very simple in vitro system. On the other hand, in vivo models more closely reproducing some of the features of human pathophysiology enabled to assess the consequences of demyelination and the molecular mechanisms of remyelination, and they are often used to validate the effect of pharmacological agents. However, they are very complex, and not suitable for large scale drug discovery screening. Recent advances in cell reprogramming, biophysics and bioengineering have allowed impressive improvements in the methodological approaches to study brain physiology and myelination. Rat and mouse OPCs can be replaced by human OPCs obtained by induced pluripotent stem cells (iPSCs) derived from healthy or diseased individuals, thus offering unprecedented possibilities for personalized disease modeling and treatment. OPCs and neural cells can be also artificially assembled, using 3D-printed culture chambers and biomaterial scaffolds, which allow modeling cell-to-cell interactions in a highly controlled manner. Interestingly, scaffold stiffness can be adopted to reproduce the mechanosensory properties assumed by tissues in physiological or pathological conditions. Moreover, the recent development of iPSC-derived 3D brain cultures, called organoids, has made it possible to study key aspects of embryonic brain development, such as neuronal differentiation, maturation and network formation in temporal dynamics that are inaccessible to traditional in vitro cultures. Despite the huge potential of organoids, their application to myelination studies is still in its infancy. In this review, we shall summarize the novel most relevant experimental approaches and their implications for the identification of remyelinating agents for human diseases such as multiple sclerosis.

